Left Ventricular Systolic Dysfunction: Causes & Treatment

Left ventricular systolic dysfunction (LVSD) means the heart’s main pumping chamber has lost some of its ability to contract and push blood out to the body. It is typically defined by a reduced left ventricular ejection fraction, a measure of how much blood the left ventricle ejects with each beat. A normal ejection fraction sits roughly between 50 and 70 percent; when it drops below 40 percent, the condition is classified as heart failure with reduced ejection fraction. The causes range from heart attacks and chronic high blood pressure to genetic mutations, toxic exposures, and conditions that resolve on their own, and treatment has evolved dramatically over the past two decades with drugs, devices, and surgical options that can slow disease progression and, in some cases, reverse it.

What Actually Happens Inside the Heart

When cardiac output falls because the left ventricle is not squeezing effectively, the body tries to compensate. Two systems ramp up almost immediately: the sympathetic nervous system (the “fight-or-flight” wiring) and the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance. In the short term, these responses help maintain blood flow by increasing heart rate, tightening blood vessels, and retaining salt and water. Over weeks and months, though, chronic activation of these same systems damages the heart further, stiffens blood vessels, and promotes fluid overload. This self-reinforcing cycle is one of the most important mechanisms driving heart failure from bad to worse, and it is why nearly every proven medication for LVSD targets one or both of these pathways.¹

Ischemic Causes

Coronary artery disease is the single most common reason a left ventricle loses pumping strength, especially in high-income countries. When a coronary artery becomes blocked, part of the heart muscle is starved of blood and dies. The dead tissue is replaced by scar, which cannot contract. Even muscle that survives the event may remain “stunned” or chronically under-perfused, functioning below capacity without being fully dead. This combination of irreversible scar and dysfunctional-but-viable tissue is what cardiologists call ischemic cardiomyopathy.² The distinction matters because viable but hibernating muscle can sometimes recover if blood flow is restored through stenting or bypass surgery, whereas scar tissue will not.

Despite improvements in how quickly heart attacks are treated, ischemic cardiomyopathy remains the leading cause of heart failure in developed nations, carrying significant rates of illness and death.³ The underlying process involves plaque buildup, clot formation, reduced blood supply, cell death, and gradual remodeling of the ventricle into a larger, thinner-walled chamber that pumps less efficiently.

Non-Ischemic Causes

When systolic dysfunction develops in the absence of blocked coronary arteries, the umbrella term is non-ischemic cardiomyopathy. The list of potential triggers is long, but a few categories stand out.

Genetic and Idiopathic Dilated Cardiomyopathy

In dilated cardiomyopathy, the left ventricle stretches out and weakens without an obvious external cause. Genetic mutations explain a substantial share of these cases. Mutations in the gene for titin, the largest protein in the human body and a critical structural component of heart muscle fibers, are found in roughly a quarter of people with dilated cardiomyopathy. In one landmark study, titin-truncating mutations appeared in 27 percent of dilated cardiomyopathy patients compared with about 3 percent of healthy controls. These mutations tracked strongly through families and showed high penetrance after age 40.⁴ Other genes are involved too, but titin remains the single most commonly affected one. When no genetic cause is found and no other explanation fits, the label “idiopathic” is used, though that proportion continues to shrink as genetic testing improves.

Toxic and Drug-Induced Damage

Certain drugs harm the heart by poisoning the energy-producing machinery inside cardiac cells. Anthracycline chemotherapy agents like doxorubicin are among the most well-known culprits, but the list extends to other cancer drugs, the antiviral zidovudine, some oral diabetes medications, and illicit substances including alcohol, cocaine, and methamphetamine.⁵ The damage typically starts before symptoms appear. Cardiac biomarkers may rise, followed by subtle changes in how the muscle deforms during contraction, and eventually a measurable drop in ejection fraction.⁶ Catching the problem at the biomarker or deformation stage, before the ejection fraction falls, gives doctors the best chance to modify treatment and protect the heart.

Pressure and Volume Overload

Long-standing high blood pressure forces the left ventricle to work harder with every beat, and the muscle gradually thickens in response. That thickening is not protective in the long run. In patients with aortic valve stenosis, for example, the greater the left ventricular mass, the lower the ejection fraction and the higher the likelihood of heart failure, independent of how severe the valve narrowing itself was.⁷ Adding hypertension on top of an already narrowed aortic valve worsens ventricular remodeling further.⁸ Severe valve leaks, such as mitral or aortic regurgitation, create volume overload rather than pressure overload, but the end result is similar: the ventricle stretches and eventually fails.

Causes That Can Reverse

Not every case of LVSD is permanent. Several forms of cardiomyopathy can improve or fully resolve once the underlying trigger is removed. Tachycardia-induced cardiomyopathy, where a persistently rapid heart rate weakens the muscle, often recovers once the rhythm is controlled. Peripartum cardiomyopathy, which strikes during late pregnancy or shortly after delivery, frequently improves over time, though lasting problems with heart function and even death are not rare.⁹ Takotsubo syndrome, triggered by intense emotional or physical stress, produces dramatic ballooning of the ventricle that mimics a heart attack, yet cardiac MRI typically shows no permanent muscle death, and function recovers relatively quickly.¹⁰ Thyroid-related and inflammation-driven cardiomyopathies round out the list of potentially reversible forms.¹¹

Identifying a reversible cause early matters enormously because standard heart failure medications may be needed only temporarily. People whose ejection fraction normalizes still need close follow-up, however, since some conditions like peripartum cardiomyopathy can recur with subsequent pregnancies.

How It Is Detected and Measured

Ejection fraction is the headline number used to gauge how well the left ventricle is pumping. It is most commonly measured by echocardiography, an ultrasound of the heart.¹² The number you get, though, depends partly on how it is measured. Cardiac MRI is considered the reference standard for accuracy, and while three-dimensional echocardiography and contrast-enhanced two-dimensional echo come close, standard two-dimensional echo without contrast tends to underestimate heart chamber volumes and shows more variability between readings.¹³ This is worth knowing because a few percentage points on an ejection fraction measurement can shift someone into or out of treatment thresholds.

Blood tests add another layer. Natriuretic peptides, substances released by stretched heart muscle, serve as useful screening tools. In the general population, these markers carry a high negative predictive value for LVSD, meaning that if the level is normal, it is extremely unlikely that the ventricle is significantly impaired.¹⁴ Where these tests fall short is in the positive direction: an elevated level flags that something may be wrong, but many other conditions (kidney disease, obesity, atrial fibrillation) can push natriuretic peptides up without LVSD being present.

Foundational Drug Therapies

Modern medical treatment for LVSD rests on four drug classes, often referred to as the “four pillars.” Each one has been shown in large trials to reduce death or hospitalization, and current guidelines recommend getting patients on all four as quickly as they can tolerate them.

RAAS Inhibitors and Sacubitril-Valsartan

ACE inhibitors and angiotensin receptor blockers have been cornerstones of treatment for decades, working by blocking the neurohormonal cascade described earlier. The newer combination drug sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor, or ARNI) pairs an angiotensin blocker with a drug that boosts the body’s own protective peptides. A meta-analysis of randomized trials found that sacubitril-valsartan reduced all-cause death by about 12 percent compared with ACE inhibitors or ARBs alone in patients with an ejection fraction at or below 40 percent, and cut heart failure rehospitalizations by about 15 percent.¹⁵ There is also evidence that switching to sacubitril-valsartan reduces the burden of dangerous heart rhythm disturbances, possibly by promoting favorable structural changes in the heart.¹⁶

After a heart attack specifically, sacubitril-valsartan did not improve ejection fraction more than the ACE inhibitor ramipril in one echocardiographic substudy, but it did limit the progressive enlargement of the ventricle and improved markers of filling pressure.¹⁷ Preventing that enlargement matters because once the ventricle stretches beyond a certain point, the remodeling becomes harder to reverse.

Mineralocorticoid Receptor Antagonists

Spironolactone and eplerenone block the effects of aldosterone, a hormone that drives fluid retention and promotes scarring of the heart muscle. In the landmark RALES trial, adding spironolactone to standard therapy for patients with severe heart failure cut the risk of death by 30 percent and reduced hospitalization for worsening heart failure by 35 percent.¹⁸ The drug also decreases collagen buildup in the heart and improves blood vessel function.¹⁹ Potassium levels need monitoring on these drugs, especially in people with kidney problems, but the survival benefit is large enough that they are considered essential.

SGLT2 Inhibitors

Originally developed for type 2 diabetes, SGLT2 inhibitors like dapagliflozin and empagliflozin have become one of the biggest recent advances in heart failure treatment. Trials have shown they reduce hospitalizations and improve quality of life in people with reduced ejection fraction regardless of whether they have diabetes.²⁰ On a structural level, adding an SGLT2 inhibitor to already-optimized background therapy led to greater improvements in left ventricular systolic function at three months compared with optimal therapy alone.²¹ The exact mechanisms are still being worked out, but they appear to involve favorable effects on fluid balance, blood pressure, kidney protection, and cellular energy metabolism.

Beta-blockers round out the four pillars. Three specific beta-blockers (carvedilol, metoprolol succinate, and bisoprolol) have proven survival benefits in heart failure with reduced ejection fraction, and they remain standard therapy. They work by shielding the heart from excessive sympathetic nervous system activation.

Emerging Medications

The pipeline beyond the four pillars is active. Omecamtiv mecarbil is a first-in-class drug that works by a fundamentally different mechanism from existing therapies: rather than blocking harmful neurohormonal pathways, it directly enhances the heart’s ability to contract. It does this by making the interaction between actin and myosin, the two proteins whose sliding motion produces every heartbeat, more efficient. The result is a longer contraction time and more blood ejected per beat, without the dangerous spikes in calcium or energy consumption seen with older inotropic drugs.²² Where exactly it will fit in treatment algorithms is still being determined, but it represents a genuinely new approach rather than a refinement of existing classes.

Device Therapies

When medications alone are not enough, implantable devices can help. Cardiac resynchronization therapy uses a specialized pacemaker to coordinate the contractions of the left and right ventricles, which often fall out of sync in heart failure patients with a wide electrical conduction pattern on ECG. In patients with mild symptoms, a wide QRS complex, and an existing indication for a defibrillator, adding CRT significantly improved ventricular size and ejection fraction over six months compared with a defibrillator alone.²³ In patients with more advanced symptoms, CRT improved quality of life, functional capacity, and exercise performance without interfering with defibrillator functions.²⁴

Implantable cardioverter-defibrillators serve a different purpose: they stand guard against sudden cardiac death from dangerous rhythm disturbances, which are disproportionately common in people with low ejection fractions. Many patients receive a combined CRT-defibrillator device that addresses both problems at once.

When the Heart Needs Mechanical Support or Replacement

For people whose condition deteriorates despite full medical and device therapy, two options remain. A left ventricular assist device is a surgically implanted pump that takes over much of the ventricle’s work, either as a bridge while awaiting a transplant or as a long-term “destination” therapy in patients who are not transplant candidates. Heart transplantation remains the definitive treatment for end-stage heart failure when other options have been exhausted. Timely referral to a specialized center for evaluation of both options plays a key role in outcomes, and delays in referral are a recognized contributor to worse results.²⁵

Exercise and Cardiac Rehabilitation

For a long time, people with a weak heart were told to rest. That advice has been turned on its head. Structured exercise programs improve how well people with reduced ejection fraction feel and function. One meta-analysis found that cardiac rehabilitation improved quality of life on at least one validated questionnaire, and individual trials have demonstrated meaningful gains in exercise capacity and functional status in people with mild-to-moderate left ventricular dysfunction, with peak exercise capacity increasing by about two metabolic equivalents after a rehabilitation program.²⁶²⁷

The structural effects are more modest. A systematic review found that exercise significantly reduced left ventricular end-diastolic diameter, a marker of chamber size, but did not consistently change ejection fraction itself compared with control groups.²⁸ In other words, exercise makes patients feel and function better, and may slow or partially reverse ventricular enlargement, but it should be seen as a complement to medication rather than a substitute for it. Interval training and moderate continuous training both appear beneficial.

Iron Deficiency and the Cardiorenal Connection

One underappreciated contributor to worsening heart failure is iron deficiency. It can sap exercise tolerance and worsen symptoms even without causing outright anemia. Observational data have identified iron deficiency as an independent predictor of death or urgent transplantation in heart failure patients, roughly increasing that risk by about 60 percent.²⁹ Studies of intravenous iron replacement have shown improvements in heart function, exercise capacity, and quality of life, and these benefits appeared regardless of whether the patient was anemic.³⁰

The kidney adds another layer of complexity. Heart failure reduces kidney blood flow, and kidney dysfunction worsens fluid retention and limits the doses of heart failure drugs a patient can tolerate. This interplay, sometimes called the cardiorenal syndrome, means that managing LVSD effectively often requires paying attention to kidney function and iron stores alongside the heart itself. Routine screening for iron deficiency is increasingly becoming standard practice in heart failure clinics, a shift that could add a relatively simple and low-risk intervention to the treatment toolkit.

Remote Monitoring of Pressures Inside the Heart

One of the challenges with heart failure management is that by the time a patient feels short of breath or gains visible fluid weight, pressures inside the heart have often been rising for days or weeks. A small implantable sensor placed in the pulmonary artery (the CardioMEMS system) allows clinicians to track those pressures remotely and adjust medications before a hospitalization becomes necessary. Randomized trials have shown that this approach reduces heart failure hospitalizations regardless of ejection fraction.³¹ In the MONITOR-HF trial, patients managed with hemodynamic monitoring had roughly half the rate of heart failure hospitalizations or urgent visits requiring intravenous diuretics compared with standard care.³² Quality of life improved substantially as well.³³

This technology is still gaining traction and is not yet universally available, but it represents a move toward proactive rather than reactive heart failure care. For patients who experience frequent hospitalizations despite seemingly optimal treatment, remote pressure monitoring may help close the gap between what medications can do and how accurately clinicians can tell when adjustments are needed.